Healthcare / BiotechnologyWarsaw
$42.90
-0.80 (-1.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-7.1M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$65M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.0%
↓Gross Margin
-1063.6%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+94.3%
FCF CAGR
—
FCF margin
-7936.4%
FCF / Net income
0.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22000.0 · net income $-6.0M · FCF $-1.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22000.00 | $22000.00 | $14000.00 | $7000.00 | $3000.00 |
| Net Income | $-6.0M | $-6.0M | $-3.6M | $-5.6M | $-4.1M |
| EBITDA | $-5.4M | $-5.4M | $-2.5M | $-4.1M | $-3.6M |
| EPS | — | — | -2.58 | -4.32 | -3.56 |
| Gross Margin | -1063.6% | -1063.6% | -2028.6% | -6742.9% | -9600.0% |
| Operating Margin | -27377.3% | -27377.3% | -29807.1% | -92100.0% | -137366.7% |
| Net Margin | -27186.4% | -27186.4% | -25935.7% | -79800.0% | -135333.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.02 | 0.02 | 0.11 |
| Current Ratio | 2.06 | 2.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.7M | $-1.7M | $-14.4M | $-7.1M | $-4.9M |
| Returns | |||||
| ROE | -24.0% | -24.0% | -15.1% | -20.1% | -72.2% |
| Valuation | |||||
| P/B | 2.63 | 2.63 | 5.79 | 4.80 | 20.29 |
| Growth & Yield | |||||
| Revenue Growth | 57.1% | 57.1% | 100.0% | 133.3% | — |
| EPS Growth | — | — | 40.3% | -21.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-42.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.58 → n/d
Residual
-42.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.